Pricing and Reimbursement Issues for Generics & Biosimilars Markets in Europe

Executive Summary

• Executive Summary

Important Terms

• Definitions

Methodology Of Research

• The "12 Step" Market Engineering Research Methodology and Process

Overview

• Market Analysis
• Scope and Objectives
• Pricing and Reimbursement
• The Biosimilars Opportunity

Pharmaceutical Cost-containment Measures

• Reference Pricing
• Parallel Trade
• Generic Substitution
• Patient Co-payments and Reimbursement

Political/Legal/Regulatory Issues

• Impact of EU Accession
• The Roche/Bolar Provision
• Data Exclusivity and Marketing Authorisation Applications

Group I

Group II

• Denmark
• Germany
• The Netherlands
• The United Kingdom

Group III

• Austria
• Belgium
• France
• Italy
• Portugal
• Spain

Market Players

Recommendations to Market Participants

DSDs